Latest News
September 20, 2021
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
September 16, 2021
Not intended for U.S. and UK Media – ESMO Congress 2021:
Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer
September 09, 2021
Not intended for U.S. and UK Media
Bayer to highlight expanded research from growing oncology portfolio at ESMO Congress 2021
September 06, 2021
Not intended for U.S. and UK Media
Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
August 31, 2021
Not intended for U.S. and UK Media
Bayer starts Phase III clinical development program OASIS with Elinzanetant
Global Health Policy Blog
Current Topics
All